

## Impact of Pulmonary and Sleep Disorders on COVID-19 Infection Severity in a Large Clinical Biobank

Brian E. Cade<sup>1,2\*</sup>, Syed Moin Hassan<sup>1,2,3</sup>, Janet M. Mullington<sup>2,4</sup>, Elizabeth W. Karlson<sup>5,6</sup>,

Susan Redline<sup>1,2</sup>

1. Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA 02115, USA
2. Division of Sleep Medicine, Harvard Medical School, Boston, MA 02115, USA
3. Division of Pulmonary Disease and Critical Care Medicine, University of Vermont, Burlington, VT 05401, USA
4. Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
5. Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA
6. Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

\*: Please address all correspondence and requests for reprints to:

Brian Cade

Division of Sleep and Circadian Disorders

Brigham and Women's Hospital, Harvard Medical School

221 Longwood Avenue, Boston, MA 02115, USA

1-857-307-0353 (phone) 1-617-278-6946 (fax) [bcade@bwh.harvard.edu](mailto:bcade@bwh.harvard.edu) (e-mail)

**Author Contributions:** Conception and design: BEC, SMH, EWK, and SR. Data acquisition: all authors. Analysis: BEC. Interpretation, draft and review, and final approval: all authors. BEC and SR had full access to the study data and take responsibility for the integrity of the data and accuracy of analyses.

**Funding:** Brian Cade is supported by grants from the American Thoracic Society Foundation

and the National Institutes of Health (R03-HL154284, R01-HL153805). Susan Redline is supported by grants from the National Institutes of Health (R35-HL135818). Elizabeth Karlson is supported by grants from the National Institutes of Health (U01-HG008685 and P30 AR070253).

**Running title:** Common pulmonary disease and Covid-19 severity

**Competing Interest Statement:** The authors declare no competing interest.

**Cade et al.: Common pulmonary disease and Covid-19 severity**

1 **Abstract**

2 **Rationale:** Multiple pulmonary, sleep, and other disorders are associated with the  
3 severity of Covid-19 infections but may or may not directly affect the etiology of acute  
4 Covid-19 infection. Identifying the relative importance of concurrent risk factors may  
5 prioritize respiratory disease outbreaks research.

6 **Objectives:** To identify associations of common preexisting pulmonary and sleep  
7 disease on acute Covid-19 infection severity, investigate the relative contributions of  
8 each disease and selected risk factors, identify sex-specific effects, and examine whether  
9 additional electronic health record (EHR) information would affect these associations.

10 **Methods:** 45 pulmonary and 6 sleep diseases were examined in 37,020 patients with  
11 Covid-19. We analyzed three outcomes: death; a composite measure of mechanical  
12 ventilation and/or ICU admission; and inpatient admission. The relative contribution of  
13 pre-infection covariates including other diseases, laboratory tests, clinical procedures,  
14 and clinical note terms was calculated using LASSO. Each pulmonary/sleep disease  
15 model was then further adjusted for covariates.

16 **Measurements and main results:** 37 pulmonary/sleep diseases were associated  
17 with at least one outcome at Bonferroni significance, 6 of which had increased relative  
18 risk in LASSO analyses. Multiple prospectively collected non-pulmonary/sleep diseases,  
19 EHR terms and laboratory results attenuated the associations between preexisting  
20 disease and Covid-19 infection severity. Adjustment for counts of prior “blood urea  
21 nitrogen” phrases in clinical notes attenuated the odds ratio point estimates of 12  
22 pulmonary disease associations with death in women by  $\geq 1$ .

23 **Conclusions:** Pulmonary diseases are commonly associated with Covid-19 infection

**Cade *et al.*: Common pulmonary disease and Covid-19 severity**

24 severity. Associations are partially attenuated by prospectively-collected EHR data,  
25 which may aid in risk stratification and physiological studies.

26

27 **Abstract word count:** 250

28 **Keywords:** COVID-19, Epidemiology, Pulmonary disorders, Sleep disorders

29

30

**Cade et al.: Common pulmonary disease and Covid-19 severity**

31 **Introduction**

32 Covid-19 continues to be an important public health problem. Prior to the  
33 Omicron wave, Covid-19 was one of the leading causes of death in the US in every age  
34 group above age 15 [1]. Thousands continue to die despite the availability of vaccines,  
35 emphasizing a continued need for research to help mitigate the effects of this and future  
36 infectious disease outbreaks.

37 The range of effects arising from Covid-19 infection, from minimal symptoms to  
38 death is striking. Less is known about the relative importance of individual pulmonary  
39 and sleep diseases contributing to infection severity in patients with multimorbidity.  
40 Examining the association of a range of pulmonary and sleep diseases with Covid-19  
41 infection severity and applying machine learning methods to identify a subset of  
42 independent associations that predict infection severity may aid in identifying  
43 etiological mechanisms of morbidity and mortality. These associations may differ by sex,  
44 given sex differences in both Covid-19 prevalence and associated risk factors.

45 Associations between preexisting pulmonary/sleep disease and Covid-19  
46 infection severity may be changing with time. The Omicron variant has reduced  
47 pulmonary pathology compared to other variants [2,3]. Patients carrying the Omicron  
48 variant have reduced risk of hospital admissions and severe infection [4]. The degree of  
49 association between individual diseases and Covid-19 severity may therefore change  
50 across different phases of the epidemic. Examining these changing environmental  
51 interactions may provide insight into the pathophysiology of both Covid-19 and the  
52 tested diseases themselves.

**Cade et al.: Common pulmonary disease and Covid-19 severity**

53 Prospective collection of data in clinical biobanks are one means of addressing  
54 these and other questions. EHR databases can leverage extensive clinical note,  
55 diagnosis, procedure, and laboratory data collected prior to infection. Natural language  
56 processing (NLP) [5] of controlled medical vocabulary concepts [6] from date-stamped  
57 clinical notes can improve disease phenotyping [7]. These clinical note concepts,  
58 together with procedure and laboratory information, can also be used to identify risk  
59 factors that complement or potentially mediate or confound the association of existing  
60 diseases with Covid-19 infection severity.

61 In this study, we report associations between common preexisting pulmonary  
62 and sleep diseases and acute Covid-19 morbidity and mortality among patients with  
63 PCR-based diagnoses of Covid-19 with data in the Mass General Brigham (MGB) EHR  
64 database from the greater Boston, MA region. We investigate the relative importance of  
65 individual preexisting diseases and ancillary EHR concepts, identify sex- and date-  
66 specific associations, and report the effect of lead EHR concepts on the associations of  
67 preexisting diseases and Covid-19 infection severity.

68

69

70 **Methods**

71 Additional details are provided in the Supplemental Methods.

72

73 Study sample

**Cade et al.: Common pulmonary disease and Covid-19 severity**

74 All patients with PCR-diagnosed Covid-19 were enrolled in the MGB Research  
75 Patient Data Registry EHR database [8,9]. Study collection ended at 6/1/2022. We used  
76 a stringent combined data floor and loyalty cohort [10] approach to minimize the  
77 number of patients with reduced documentation (and increased risk of false negative  
78 associations) [11] by requiring at least three clinical notes, encounters, and diagnoses.  
79 We also required at least 7 clinical facts: one diagnosis, encounter, laboratory result,  
80 medication, outpatient visit, routine visit [10], and vital sign obtained before 2020.  
81 Children, MGB employees, and patients living outside of Massachusetts or without  
82 available race/ethnicity, age, biological sex, or BMI values were excluded.

83

84 Data used

85 The acute phase of infection for measuring ICU admissions, mechanical  
86 ventilation, and inpatient admissions was defined as -7 to +30 days relative to the first  
87 positive PCR test (we did not analyze Covid-19 reinfections) in the EHR. Diseases,  
88 procedures, and NLP terms recorded at least 8 days prior to the PCR test were  
89 extracted. Laboratory measurements were extracted from -5 to -1 years prior to the PCR  
90 test. A breakthrough infection was defined as having occurred over 30 days after a  
91 second vaccination. Majority variant date ranges were based on Broad Institute Covid-  
92 19 Genome Surveillance project sequencing in the greater Boston area. Transition dates  
93 from the pre-Delta to the Delta and Omicron variants were set at 7/3/2021 and  
94 12/17/2021 respectively.

95 Diseases were based on PheCode groupings of ICD codes [12,13] (**Table S1**) and

**Cade et al.: Common pulmonary disease and Covid-19 severity**

98 refined using natural language processing. We evaluated 45 common ( $\geq 1\%$  prevalence in  
99 patients with Covid-19) and selected rare pulmonary disorders and 6 common sleep  
100 disorders [14–16]. Clinical note concept terms were extracted using NLP and mapped to  
101 Concept Unique Identifiers (CUIs) codes [5,6]. Terms that matched disease names were  
102 used to improve disease phenotyping using multimodal automated phenotyping (MAP)  
103 [7]. We included all non-pulmonary and non-sleep diseases defined using PheCodes and  
104 MAP with  $>1\%$  prevalence among patients with Covid-19 in LASSO regression analyses  
105 (described below). Given the sparse nature of certain individual procedures, we also  
106 grouped procedures as specified by AHRQ Clinical Classification Software (CCS,  
107 <https://www.hcup-us.ahrq.gov/toolssoftware/ccs10/ccs10.jsp>). Procedure and CUI IDs  
108 for variables retained after LASSO regressions are listed in Table S6.

109 We documented evidence of continuous positive airway pressure (CPAP) use  
110 among patients with at least one clinical encounter and one clinical note from -365 to -8  
111 days prior to the first positive PCR test. Total counts of five related procedures and one  
112 NLP term (Table S5) were combined. CPAP evidence in the prior year was present for  
113 2,946 / 4,027 (73.1%) of the eligible patients with sleep apnea.

114 In an exploratory aim, we examined whether selected hematology laboratory  
115 results were associated with Covid-19 severity. We included kidney function measures  
116 given the retention of kidney disease in the LASSO results. The median values of  
117 laboratory results for individual patients from -5 to -1 years were tested with and  
118 without rank normalization. The 23 laboratory measurements were available for 65 –  
119 89% of the patients (Table S8).



**Cade et al.: Common pulmonary disease and Covid-19 severity**

120

121 Statistical analyses

122 Logistic regression included 45 pulmonary disorders, 6 sleep disorders, was  
123 adjusted for age, sex at birth, WHO obesity classification, race/ethnicity, and  
124 breakthrough infection status to predict 3 outcomes: death, mechanical ventilation or  
125 ICU admission, or inpatient admissions. The effect of CPAP evidence was tested using  
126 logistic regression with further adjustment for a single CPAP evidence term.

127 Adaptive LASSO regression used training and testing sets, each with cross-  
128 validation. Non-zero coefficient terms were carried forward to the training run and then  
129 to the final combined sample run. Age, sex, BMI, race/ethnicity, breakthrough infection  
130 status, healthcare encounter counts, and days into the pandemic were forced into runs.  
131 Laboratory results were not included due to reduced sample size and non-random  
132 ascertainment. We opted to include sex-specific terms in combined sex analyses and  
133 evaluate them in separate sex-stratified analyses. Finally, the potential effect of lead  
134 LASSO variables on disease associations with Covid-19 infection severity was assessed  
135 using logistic regression with standard covariates that included and excluded individual  
136 LASSO variables as covariates.

137

138

139 **Results**

140 Sample characteristics

141 Sample characteristics are listed in **Table 1**. The initial sample of patients with  
142 Covid-19 (through 6/1/2022) and suitable data to clear a data floor was 37,020. Women

**Cade et al.: Common pulmonary disease and Covid-19 severity**

143 represented a majority of infections (62%) but a minority of patients with more severe  
144 death and mechanical ventilation, or ICU admission outcomes (48%). The majority of  
145 breakthrough infections were in women (62%). At the time of the data freeze  
146 (6/1/2022), the number of patients with an incident diagnosis during the pre-Delta  
147 majority variant virus dates was slightly less than the combined number of patients with  
148 a diagnosis during the Delta or Omicron majority variant diagnosis dates. The median  
149 BMI has decreased for Omicron majority variant diagnosis dates, as has the percentage  
150 of Hispanic/Latino Americans among patients with an incident Covid-19 infection. The  
151 prevalence of 45 pulmonary and 6 sleep diseases grouped by PheCodes (**Table S1**) may  
152 be reduced due to the strict case criteria used by NLP-defined phenotyping. The median  
153 number of preexisting pulmonary and sleep diseases diagnosed for patients with an  
154 adverse Covid-19 outcome was higher than the median number of preexisting diseases  
155 for all patients with Covid-19.

156

157 Associations between existing disease with Covid-19 infection severity

158 The associations between existing diseases and Covid-19 infection severity are  
159 described in **Table 2**. Models included adjustment for breakthrough infection, age, sex  
160 at birth, obesity severity, and self-reported race/ethnicity. 42 of 51 diseases were  
161 nominally associated with any outcome ( $p < 0.05$ ). 37 diseases were associated with an  
162 outcome at Bonferroni significance ( $p < 3.3 \times 10^{-4}$ ): 25, 23, and 37 diseases were  
163 associated with risk of death, mechanical ventilation or ICU admission, and inpatient  
164 admission, respectively. Chronic pharyngitis and nasopharyngitis and septal  
165 deviations / turbinate hypertrophy were inversely associated with risk of mechanical

**Cade et al.: Common pulmonary disease and Covid-19 severity**

166 ventilation or ICU admission at modest significance.

167 We analyzed sex-specific associations between existing diseases and Covid-19  
168 infection severity. Death outcome results are shown in **Table 3**, with full results  
169 provided in **Table S2**. 27 and 33 diseases were associated with at least one infection  
170 severity outcome in men and women respectively at Bonferroni significance ( $p < 1.1 \times$   
171  $10^{-4}$ ). While multiple diseases displayed notably different odds ratio point estimates, sex  
172  $\times$  disease interaction p-values were generally modest in this cohort with stringent  
173 loyalty and data floor criteria. Associations between existing diseases and Covid-19  
174 infection severity in different age groups are provided in **Table S3**.

175 We examined associations between existing disease and Covid-19 incident  
176 infection severity during days when the pre-Delta, Delta, and Omicron virus variants  
177 comprised the majority of samples sequenced from the greater Boston area. **Table 4**  
178 lists the composite outcome results, with full results and sex-stratified results listed in  
179 **Table S4**. The pre-Delta, Delta, and Omicron majority variant date analyses were all  
180 adjusted for breakthrough infection status. 31 and 26 diseases were associated with any  
181 outcome during pre-Delta and Omicron variant majority dates respectively (Bonferroni  
182  $p < 1.1 \times 10^{-4}$ ). Seven diseases significantly associated with a death outcome during pre-  
183 Delta variant majority dates ( $p < 1.1 \times 10^{-4}$ ) were notably attenuated ( $p > 0.01$ ) during  
184 Omicron variant majority dates (bacterial infection NOS, empyema and pneumothorax,  
185 epistaxis or throat hemorrhage, pneumonia, pulmonary hypertension, sleep apnea, and  
186 symptoms involving respiratory system and other chest symptoms). Conversely, a  
187 modest association between solitary pulmonary nodule and the death outcome during  
188 pre-Delta variant majority dates strengthened to Bonferroni significance during

**Cade et al.: Common pulmonary disease and Covid-19 severity**

189 Omicron variant majority dates.

190

191 Effects of continuous airway positive pressure

192 We examined whether adjusting for evidence of continuous positive airway  
193 pressure (CPAP) usage in clinical notes and procedures in the year prior to infection  
194 would attenuate the associations with sleep apnea, given the trends we identified in our  
195 previous report with a smaller sample size [14]. All associations with sleep apnea were  
196 attenuated ( $p > 0.02$ , **Table S5**).

197

198 Relative importance of individual existing diseases and EHR information

199 Given the large number of associated diseases and elevated multimorbidity  
200 (18.8% of the patients carried  $\geq 5$  of the tested diseases), we analyzed the relative  
201 importance of individual existing diseases affecting the risk of Covid-19 infection  
202 severity. We performed adaptive LASSO in the combined sex and sex-stratified datasets  
203 by including all pulmonary and sleep diseases and multiple covariates. Non-zero  
204 coefficients from the outcome results are shown in **Tables 5 and S6**, with larger  
205 absolute values indicating greater importance for individual variables. Chronic airway  
206 obstruction, pneumonia, and respiratory failure had non-zero coefficients for the death  
207 outcome.

208 We next leveraged additional EHR information by performing similar adaptive  
209 LASSO analyses to identify factors with greater importance using separate analyses of  
210 505 non-pulmonary/sleep diseases, 1,647 procedures, 171 CCS grouped procedures, and  
211 9,839 clinical note NLP terms. Results for non-zero coefficient terms are listed in **Table**

**Cade et al.: Common pulmonary disease and Covid-19 severity**

212 **S6.** 124 EHR variables were identified in the combined sex analyses. Six non-  
213 pulmonary/sleep diseases and ICD-coded procedures had non-zero coefficient terms in  
214 the combined-sex death outcome analysis: chronic renal failure, chemotherapy, altered  
215 mental status, essential hypertension, thrombocytopenia, and abnormality of gait.  
216 Associations between LASSO terms and Covid-19 infection severity adjusted for  
217 covariates are presented in **Table S7**. Multiple non-pulmonary diseases were associated  
218 with the death outcome, including chronic renal failure (OR 3.61, 95% CI 3.04 – 4.28)  
219 and thrombocytopenia (OR 3.19, 95% CI 2.45 – 4.17).

220

221 Predictive laboratory values

222 Complete blood count and other hematology measurements are commonly  
223 collected in many patients undergoing hospital procedures. As an exploratory aim, we  
224 examined whether the median values of these measurements collected 1 – 5 years prior  
225 to the incident Covid-19 diagnosis were associated with infection severity. We also  
226 included measures of kidney function, given the identification of kidney disease in the  
227 LASSO results. 17 of the 23 laboratory tests were associated with at least one outcome in  
228 the available sample at Bonferroni significance (65 – 89% coverage of patients), using  
229 logistic regression with adjustment for covariates (**Table S8**). Estimated glomerular  
230 filtration rate, hematocrit, hemoglobin, and red cell distribution width results were the  
231 most notable associated measures with all p-values  $\leq 2.0 \times 10^{-16}$ , despite the  
232 identification of thrombocytopenia and elevated white blood cell counts PheCodes in the  
233 LASSO results.

234

**Cade et al.: Common pulmonary disease and Covid-19 severity**

235 Associated EHR concepts attenuate disease associations

236 Finally, we examined whether individual retained LASSO terms and prior  
237 hematology and kidney laboratory results would attenuate the associations between  
238 individual diseases and infection severity when included individually as model covariate  
239 terms. The lead terms with the highest median point estimate adjustment differences  
240 across all disease associations with the death outcome are shown in **Figure 1**. Lead  
241 terms spanned a range of healthcare procedures, laboratory results, and pulmonary and  
242 non-pulmonary diseases. Full results are provided in **Table S9**, and additional  
243 visualizations are provided in **Figures S1 – S17**. Adjustment for “blood urea nitrogen”  
244 clinical note phases attenuated the odds ratio point estimates of 12 pulmonary disease  
245 associations with death in women by  $\geq 1.0$ .

246

247

248 **Discussion**

249 In this study, we examined the association of preexisting pulmonary, sleep, and  
250 other diseases with the risk of acute Covid-19 infection severity and investigated other  
251 factors that may alter those associations. Notable results include (a) common  
252 associations between dozens of pulmonary disorders and infection severity, some of  
253 which are protective; (b) changes in disease associations across date periods with  
254 different SARS-CoV-2 majority variants, with attenuated associations with death for 7  
255 diseases, and an increased point estimate for 1 disease; (c) an increased importance of  
256 specific pulmonary disease associations with Covid-19 severity relative to other  
257 comorbid pulmonary and sleep diseases; (d) associations between infection severity and

**Cade *et al.*: Common pulmonary disease and Covid-19 severity**

258 multiple hematology and kidney-related laboratory results collected 1 – 5 years prior to  
259 infection; and (e) non-pulmonary/sleep diseases, laboratory results, hospital  
260 procedures, and clinical note terms that attenuate and sometimes increase the  
261 associations between pulmonary and sleep diseases with Covid-19 infection severity.  
262 These results may aid in further understanding the etiology of a changing disease.

263 We observed common associations between preexisting pulmonary and sleep  
264 diseases with Covid-19 infection severity, including 37 of the 51 tested diseases  
265 associated with at least one outcome at Bonferroni significance (Tables 2 and S2).  
266 Certain diseases (e.g. asthma) can confer different risks for men and women, although  
267 sex × disease interaction p-values tended to be modest (Tables 3 and S2). Acute sinusitis  
268 has a protective association with the death measure in men (0.33 OR, 95% CI 0.14 –  
269 0.77,  $p = 9.8 \times 10^{-3}$ ) that is not present in women (0.94 OR, 95% CI 0.61 – 1.43,  $p =$   
270 0.76). A similar but more modest association was also observed between the death  
271 outcome and acute upper respiratory infections. These findings may help improve the  
272 personalization of treatment for patients with increased Covid-19 morbidity.

273 The associations between preexisting disease and infection severity are changing  
274 across time for certain diseases (Tables 4 and S4). Notable diseases with attenuated  
275 associations with death during Omicron-majority variant periods compared to pre-Delta  
276 majority variant periods include bacterial infection NOS (3.00 OR [95% CI 2.16 - 4.16]  
277 pre-Delta period; 1.63 [0.90 - 2.95] Omicron period), sleep apnea (1.83 [1.44 - 2.33] pre-  
278 Delta period; 1.35 [0.89 - 2.04] Omicron period), and influenza (1.72 [1.29 - 2.30] pre-  
279 Delta period; 0.90 [0.53 - 1.55] Omicron period). These changes may reflect differences  
280 in SARS-CoV-2 pathogenicity in upper and lower respiratory tracts [2,3]. The

**Cade et al.: Common pulmonary disease and Covid-19 severity**

281 differences in outcomes across majority variant strain periods are consistent with a  
282 recent report examining the same dataset using independent methods [17]. Differences  
283 in risk factors and outcomes have potential study design implications for acute and  
284 possibly Long Covid research. The changing nature of SARS-CoV-2 associations with a  
285 range of comorbidities could potentially provide a window for future physiological  
286 research examining how individual pulmonary and sleep diseases increase risk for  
287 outcomes in other diseases.

288         Our study sample has a high degree of multimorbidity, and 39 pre-existing  
289 diseases were associated with at least one infection severity outcome at Bonferroni  
290 significance. We therefore performed LASSO regression analyses to identify the relative  
291 importance of specific diseases (Tables 5 and S6). LASSO analyses minimize the number  
292 of factors that collectively may predict an outcome. Six pulmonary diseases were  
293 retained: chronic airway obstruction, respiratory failure, pneumonia, emphysema,  
294 pulmonary congestion and hypostasis, and shortness of breath (Table 5). These diseases  
295 may be enriched with pathophysiological mechanisms that contribute increased risk  
296 across the broader range of pulmonary and sleep disorders associated with acute Covid-  
297 19 infection severity.

298         Preexisting non-pulmonary diseases, hospital procedures and clinical note terms  
299 identified by LASSO regression and laboratory results may have predictive value for  
300 Covid-19 infection severity, given the common associations between preexisting  
301 pulmonary disease and Covid-19 infection severity (Table S6). These variables may  
302 potentially mediate or confound associations between preexisting pulmonary and sleep  
303 diseases and infection severity (Table S9 and Figures 1, S1 – S17) or could reflect the



**Cade et al.: Common pulmonary disease and Covid-19 severity**

304 effects of other factors unmeasured in this study. Five non-pulmonary PheCode-  
305 encoded diseases (and chemotherapy) were associated with death: chronic renal failure,  
306 altered mental status, essential hypertension, thrombocytopenia, and abnormality of  
307 gait. We chose to analyze procedures and all NLP term with common frequencies in  
308 order to identify factors that could help predict outcome severity, even if they are  
309 unlikely to be directly related to pathophysiology. Some lead terms that attenuate the  
310 associations of multiple diseases are related to healthcare utilization (e.g. hospital  
311 discharge procedures and “normal diet” text phrases) that are consistent with  
312 multimorbidity increasing the risk of adverse Covid-19 infection outcomes. Adjustment  
313 for electrocardiogram procedures and red cell distribution width laboratory results also  
314 attenuated the median point estimate of pulmonary and sleep disease associations with  
315 the death outcome more than adjustment for any pulmonary disease. The most notable  
316 variable to broadly affect associations with death was “blood urea nitrogen” in analyses  
317 of women (Figures S12 and S13), which attenuated the point estimates of 12 diseases by  
318  $>1$  and the statistical significance of 13 diseases ( $p > 0.05$ ), although a smaller effect was  
319 observed when adjusting for actual median urea nitrogen blood levels collected from -5  
320 to -1 years prior to infection with Covid-19. Adjustment for chronic renal failure and  
321 creatinine and estimated glomerular filtration rate laboratory results also support a role  
322 for kidney malfunction contributing to pulmonary and sleep disease associations with  
323 deaths in women.

324         Seventeen of 23 prospectively collected hematology and kidney function  
325 laboratory tests were associated with Covid-19 outcome severity at Bonferroni  
326 significance (Table S8). Estimated glomerular filtration rate and three red blood cell

**Cade et al.: Common pulmonary disease and Covid-19 severity**

327 tests were the most significantly associated tests across all models. The laboratory value  
328 ranges may reflect physiological changes due to both known and unknown risk factors  
329 and may be useful as a general risk stratification measure. These associations were  
330 based on a subset of patients with available data, and the associations could possibly  
331 also reflect differences in test ordering (e.g. kidney test results may be disproportionately  
332 missing for patients whose clinicians do not suspect kidney malfunction). Additional  
333 follow-up in a broader range of patients is needed to understand the generalization of  
334 these results. The prediction models could be readily improved beyond these initial  
335 exploratory results.

336         The strengths of this study include an extensive sample size of patients diagnosed  
337 using PCR testing, which has allowed us to perform sex-, age-, and majority SARS-CoV-  
338 2 strain date-specific analyses with increased study power. Data were restricted by  
339 stringent combined “data floor” and loyalty cohort criteria. We included patients with  
340 minimal clinical encounters, notes, diagnoses and evidence of seven clinical facts each  
341 collected before the pandemic in order to increase the reliability of our findings in an  
342 open environment where some patient records may be located in other healthcare  
343 systems. All disease and healthcare utilization information was collected prior to Covid-  
344 19 infection to eliminate potential reverse causation effects. All disease phenotyping  
345 included natural language processing to increase the positive predictive value in the face  
346 of rule-out diagnoses and other potential biases. We extensively studied the potential  
347 effect of dozens of pulmonary disease on Covid-19 infection severity, which enabled us  
348 to identify the relative importance of pulmonary and disease on infection severity.

349         Weaknesses are also possible with this study design. Despite inclusion of over

**Cade et al.: Common pulmonary disease and Covid-19 severity**

350 37,000 patients, this was a single healthcare system study. While the Mass General  
351 Brigham system is comprised of multiple hospitals, our results may or may not  
352 completely generalize to other healthcare systems. Loss to follow-up and missing data  
353 from out-of-network care may affect our results and those of similarly designed studies.  
354 Temporal effects may be confounded by changes in PCR testing availability and use and  
355 standards of care (e.g. proning). Patients with different financial means may have  
356 different levels of healthcare utilization, which may influence the recording of diseases,  
357 procedures, and NLP phrases differently. The diseases, procedures, and note terms  
358 identified by LASSO regression may not completely generalize, despite cross-validation  
359 and separate training and testing sets. Individual terms with lower LASSO coefficients,  
360 terms that were not individually associated with outcomes (Table S7), or terms that do  
361 not affect multiple disease associations may have increased likelihood of site-specific  
362 associations or may indirectly measure factors not included in our study design. While  
363 the majority of the patients had undergone all of the laboratory testing (Table S8), there  
364 is likely some selection bias present for patients with clinically relevant diagnoses,  
365 although some of our results are supported by orthogonal diagnosis and NLP term data  
366 (Table S7).

367

368

369 **Conclusions**

370 We identified common associations between preexisting pulmonary disease and  
371 Covid-19 infection severity and identified specific diseases with increased relative  
372 importance in our patient sample with multimorbidity. Certain associations are

**Cade *et al.*: Common pulmonary disease and Covid-19 severity**

373 majority-variant date specific. We also identified several non-pulmonary diseases,  
374 clinical procedures, and clinical note phrases that potentially mediate or confound these  
375 associations. These results may aid in further understanding the etiology of a changing  
376 disease.

**Cade et al.: Common pulmonary disease and Covid-19 severity**

**References**

- 1 Shiels MS, Haque AT, Berrington de González A, et al. Leading Causes of Death in the US During the COVID-19 Pandemic, March 2020 to October 2021. *JAMA Intern Med* 2022;**182**:883–6. doi:10.1001/jamainternmed.2022.2476
- 2 Armando F, Beythien G, Kaiser FK, et al. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. *Nat Commun* 2022;**13**:3519. doi:10.1038/s41467-022-31200-y
- 3 McMahan K, Giffin V, Tostanoski LH, et al. Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. *Med N Y N* 2022;**3**:262-268.e4. doi:10.1016/j.medj.2022.03.004
- 4 Fall A, Eldesouki RE, Sachithanandham J, et al. The displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation of hospital admissions and upper respiratory viral loads. *EBioMedicine* 2022;**79**:104008. doi:10.1016/j.ebiom.2022.104008
- 5 Savova GK, Masanz JJ, Ogren PV, et al. Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications. *J Am Med Inform Assoc JAMIA* 2010;**17**:507–13. doi:10.1136/jamia.2009.001560
- 6 Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. *Nucleic Acids Res* 2004;**32**:D267-270. doi:10.1093/nar/gkh061
- 7 Liao KP, Sun J, Cai TA, et al. High-throughput multimodal automated phenotyping (MAP) with application to PheWAS. *J Am Med Inform Assoc* Published Online First: 7 August 2019. doi:10.1093/jamia/ocz066
- 8 Boutin NT, Schechter SB, Perez EF, et al. The Evolution of a Large Biobank at Mass General Brigham. *J Pers Med* 2022;**12**:1323. doi:10.3390/jpm12081323
- 9 Karlson EW, Boutin NT, Hoffnagle AG, et al. Building the Partners HealthCare Biobank at Partners Personalized Medicine: Informed Consent, Return of Research Results, Recruitment Lessons and Operational Considerations. *J Med* 2016;**6**.
- 10 Weber GM, Adams WG, Bernstam EV, et al. Biases introduced by filtering electronic health records for patients with “complete data.” *J Am Med Inform Assoc JAMIA* 2017;**24**:1134–41. doi:10.1093/jamia/ocx071
- 11 Robinson JR, Wei W-Q, Roden DM, et al. Defining Phenotypes from Clinical Data to Drive Genomic Research. *Annu Rev Biomed Data Sci* 2018;**1**:69–92. doi:10.1146/annurev-biodatasci-080917-013335
- 12 Wei W-Q, Bastarache LA, Carroll RJ, et al. Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. *PloS One* 2017;**12**:e0175508. doi:10.1371/journal.pone.0175508
- 13 Wu P, Gifford A, Meng X, et al. Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and Initial Evaluation. *JMIR Med Inform* 2019;**7**:e14325. doi:10.2196/14325

**Cade et al.: Common pulmonary disease and Covid-19 severity**

- 14 Cade BE, Dashti HS, Hassan SM, *et al.* Sleep Apnea and COVID-19 Mortality and Hospitalization. *Am J Respir Crit Care Med* 2020;**202**:1462–4. doi:10.1164/rccm.202006-2252LE
- 15 Jones SE, Maisha FI, Strausz SJ, *et al.* The public health impact of poor sleep on severe COVID-19, influenza and upper respiratory infections. *MedRxiv Prepr Serv Health Sci* 2022;:2022.02.16.22271055. doi:10.1101/2022.02.16.22271055
- 16 Davis HE, Assaf GS, McCorkell L, *et al.* Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine* 2021;**38**:101019. doi:10.1016/j.eclinm.2021.101019
- 17 Strasser ZH, Greifer N, Hadavand A, *et al.* Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England. *JAMA Netw Open* 2022;**5**:e2238354. doi:10.1001/jamanetworkopen.2022.38354

*Cade et al.: Common pulmonary disease and Covid-19 severity*

**Figure Legends**

379 **Figure 1. Effect of lead LASSO terms and laboratory results on disease**  
380 **associations with Covid-19 death outcome.**

381 The y axis includes all pulmonary and sleep diseases associated with death in the  
382 combined sex analyses (Table 2). Lead LASSO terms (Table S6) and laboratory results  
383 (Table S8) were included individually as covariates in each of these disease associations.  
384 The odds ratio difference when including versus not including an adjusted covariate are  
385 shown as circles, with darker red indicating an attenuated odds ratio for the Y-axis  
386 disease association with death when adjusting for the X-axis covariate. The X-axis  
387 covariates are ordered by median value of point estimates considering all of the Y-axis  
388 diseases. Additional visualizations considering the three outcomes presented as point  
389 estimate and p-value differences are provided in Figures S1 – S15. Full results with  
390 sortable values are provided in Table S9.

**Cade et al.: Common pulmonary disease and Covid-19 severity**

**Tables**

**Table 1. Sample characteristics.**

	<b>All</b>	<b>Death Outcome</b>	<b>Composite Outcome</b>	<b>Inpatient Outcome</b>	<b>Breakthrough Infection</b>	<b>Pre-Delta variant majority dates</b>	<b>Delta variant majority dates</b>	<b>Omicron variant majority dates</b>
N	37,020	924	1,166	4,338	15,472	18,154	4,916	13,950
Women	22,818 (61.6)	443 (47.9)	558 (47.9)	2,359 (54.4)	9,614 (62.1)	11,026 (60.7)	2,925 (59.5)	8,867 (63.6)
Age	54.1 (25.3)	78.5 (17.7)	68.8 (20.8)	69.2 (23.4)	56.0 (25.0)	53.7 (24.9)	54.3 (25.5)	54.8 (25.8)
BMI	28.3 (8.0)	26.6 (8.5)	29.2 (8.4)	28.8 (8.6)	27.7 (8.1)	28.7 (7.9)	28.1 (7.9)	27.7 (8.2)
Race/ethnicity								
European American	26,659 (72.0)	768 (83.1)	782 (67.1)	2,996 (69.1)	12,422 (80.3)	11,951 (65.8)	4,021 (81.8)	10,687 (76.6)
Hispanic/Latino American	3,764 (10.2)	55 (6.0)	155 (13.3)	519 (12.0)	784 (5.1)	2,716 (15.0)	201 (4.1)	847 (6.1)
African American	3,176 (8.6)	55 (6.0)	129 (11.1)	495 (11.4)	978 (6.3)	1,731 (9.5)	343 (7.0)	1,102 (7.9)
Other	3,421 (9.2)	46 (5.0)	100 (8.6)	328 (7.6)	1,288 (8.3)	1,756 (9.7)	351 (7.1)	1,314 (9.4)
Pulmonary and sleep diseases	2 (3)	4 (6)	3 (5)	3 (5)	2 (3)	2 (3)	2 (3)	2 (3)
Acute bronchitis and bronchiolitis	2,479 (6.7)	92 (10.0)	129 (11.1)	446 (10.3)	992 (6.4)	1,259 (6.9)	323 (6.6)	897 (6.4)



**Cade et al.: Common pulmonary disease and Covid-19 severity**

Acute pharyngitis	5,276 (14.3)	41 (4.4)	101 (8.7)	368 (8.5)	2,240 (14.5)	2,429 (13.4)	715 (14.5)	2,132 (15.3)
Acute sinusitis	2,434 (6.6)	31 (3.4)	59 (5.1)	216 (5.0)	1,152 (7.5)	1,088 (6.0)	320 (6.5)	1,026 (7.4)
Acute upper respiratory infections of multiple or unspecified sites	5,204 (14.1)	89 (9.6)	146 (12.5)	494 (11.4)	2,345 (15.2)	2,361 (13.0)	716 (14.6)	2,127 (15.3)
Allergy	8,596 (23.2)	193 (20.9)	283 (24.3)	967 (22.3)	3,841 (24.8)	3,924 (21.6)	1,162 (23.6)	3,510 (25.2)
ARDS	300 (0.8)	32 (3.5)	38 (3.3)	123 (2.8)	130 (0.8)	150 (0.8)	39 (0.8)	111 (0.8)
Asphyxia and hypoxemia	531 (1.4)	79 (8.6)	68 (5.8)	276 (6.4)	215 (1.4)	270 (1.5)	61 (1.2)	200 (1.4)
Asthma	6,103 (16.5)	134 (14.5)	225 (19.3)	777 (17.9)	2,590 (16.7)	2,838 (15.6)	821 (16.7)	2,444 (17.5)
Bacterial infection NOS	1,324 (3.6)	87 (9.4)	79 (6.8)	287 (6.6)	500 (3.2)	676 (3.7)	177 (3.6)	471 (3.4)
Bronchitis	2,058 (5.6)	102 (11.0)	109 (9.4)	395 (9.1)	943 (6.1)	937 (5.2)	290 (5.9)	831 (6.0)
Chronic airway obstruction	1,165 (3.2)	167 (18.1)	144 (12.4)	504 (11.6)	505 (3.3)	576 (3.2)	143 (2.9)	446 (3.2)
Chronic bronchitis	549 (1.5)	76 (8.2)	67 (5.8)	261 (6.0)	226 (1.5)	264 (1.5)	57 (1.2)	228 (1.6)
Chronic pharyngitis and nasophary	1,780 (4.8)	47 (5.1)	45 (3.9)	207 (4.8)	828 (5.4)	804 (4.4)	249 (5.1)	727 (5.2)

**Cade et al.: Common pulmonary disease and Covid-19 severity**

ngitis								
Chronic sinusitis	2,051 (5.5)	39 (4.2)	56 (4.8)	221 (5.1)	981 (6.3)	903 (5.0)	282 (5.7)	866 (6.2)
Chronic tonsillitis and adenoiditis	608 (1.6)	5 (0.5)	11 (0.9)	47 (1.1)	263 (1.7)	262 (1.4)	99 (2.0)	247 (1.8)
Cough	7,152 (19.3)	272 (29.4)	324 (27.8)	1,202 (27.7)	3,247 (21.0)	3,326 (18.3)	945 (19.2)	2,881 (20.7)
Emphysema	716 (1.9)	98 (10.6)	97 (8.3)	311 (7.2)	326 (2.1)	332 (1.8)	95 (1.9)	289 (2.1)
Empyema and pneumothorax	602 (1.6)	62 (6.7)	53 (4.6)	197 (4.5)	284 (1.8)	269 (1.5)	92 (1.9)	241 (1.7)
Epistaxis or throat hemorrhage	1,185 (3.2)	80 (8.7)	64 (5.5)	226 (5.2)	514 (3.3)	564 (3.1)	168 (3.4)	453 (3.3)
Hypersomnia	584 (1.6)	17 (1.8)	24 (2.1)	86 (2.0)	265 (1.7)	261 (1.4)	73 (1.5)	250 (1.8)
Influenza	2,442 (6.6)	100 (10.8)	125 (10.7)	455 (10.5)	1,035 (6.7)	1,195 (6.6)	284 (5.8)	963 (6.9)
Insomnia	3,398 (9.2)	111 (12.0)	140 (12.0)	488 (11.3)	1,605 (10.4)	1,503 (8.3)	420 (8.5)	1,475 (10.6)
Lung cancer	329 (0.9)	51 (5.5)	26 (2.2)	130 (3.0)	163 (1.1)	147 (0.8)	38 (0.8)	144 (1.0)
Lymphangioleiomyomatosis and others	182 (0.5)	33 (3.6)	22 (1.9)	82 (1.9)	97 (0.6)	74 (0.4)	24 (0.5)	84 (0.6)
Other diseases of lung	1,279 (3.5)	138 (14.9)	112 (9.6)	446 (10.3)	546 (3.5)	646 (3.6)	147 (3.0)	486 (3.5)
Other dyspnea	2,931 (7.9)	228 (24.7)	221 (19.0)	828 (19.1)	1,366 (8.8)	1,336 (7.4)	382 (7.8)	1,213 (8.7)
Other upper	3,664 (9.9)	92 (10.0)	114 (9.8)	471 (10.9)	1,819 (11.8)	1,508 (8.3)	488 (9.9)	1,668 (12.0)

**Cade et al.: Common pulmonary disease and Covid-19 severity**

respiratory disease								
Painful respiration	2,176 (5.9)	77 (8.3)	102 (8.8)	412 (9.5)	903 (5.8)	1,044 (5.8)	275 (5.6)	857 (6.1)
Parasomnia	199 (0.5)	7 (0.8)	6 (0.5)	33 (0.8)	82 (0.5)	99 (0.6)	29 (0.6)	71 (0.5)
Pleurisy; pleural effusion	1,017 (2.8)	145 (15.7)	120 (10.3)	421 (9.7)	457 (3.0)	483 (2.7)	126 (2.6)	408 (2.9)
Pneumonia	2,375 (6.4)	224 (24.2)	212 (18.2)	779 (18.0)	1,065 (6.9)	1,122 (6.2)	299 (6.1)	954 (6.8)
Postnasal drip	1,318 (3.6)	43 (4.7)	47 (4.0)	188 (4.3)	665 (4.3)	557 (3.1)	177 (3.6)	584 (4.2)
Pulmonary collapse; interstitial and compensatory emphysema	1,198 (3.2)	153 (16.6)	124 (10.6)	505 (11.6)	553 (3.6)	579 (3.2)	146 (3.0)	473 (3.4)
Pulmonary congestion and hypostasis	722 (2.0)	123 (13.3)	111 (9.5)	398 (9.2)	304 (2.0)	368 (2.0)	86 (1.8)	268 (1.9)
Pulmonary embolism and infarction, acute	649 (1.8)	55 (6.0)	58 (5.0)	200 (4.6)	287 (1.9)	300 (1.7)	93 (1.9)	256 (1.8)
Pulmonary fibrosis	266 (0.7)	42 (4.6)	30 (2.6)	110 (2.5)	120 (0.8)	132 (0.7)	23 (0.5)	111 (0.8)
Pulmonary hypertension	366 (1.0)	60 (6.5)	54 (4.6)	175 (4.0)	166 (1.1)	175 (1.0)	49 (1.0)	142 (1.0)
Respirator	471	83	86 (7.4)	252	189 (1.2)	238 (1.3)	55 (1.1)	178 (1.3)

**Cade et al.: Common pulmonary disease and Covid-19 severity**

y failure	(1.3)	(9.0)		(5.8)				
Restless legs syndrome	456 (1.2)	26 (2.8)	29 (2.5)	91 (2.1)	215 (1.4)	210 (1.2)	56 (1.1)	190 (1.4)
Septal deviations / turbinate hypertrophy	1,321 (3.6)	22 (2.4)	23 (2.0)	94 (2.2)	643 (4.2)	543 (3.0)	204 (4.2)	574 (4.1)
Shortness of breath	3,729 (10.1)	273 (29.6)	270 (23.2)	1,063 (24.5)	1,729 (11.2)	1,663 (9.2)	463 (9.4)	1,603 (11.5)
Sleep apnea	4,240 (11.5)	166 (18.0)	215 (18.4)	717 (16.5)	1,946 (12.6)	1,962 (10.8)	596 (12.1)	1,682 (12.1)
Sleep disorders	1,260 (3.4)	41 (4.4)	43 (3.7)	214 (4.9)	541 (3.5)	616 (3.4)	160 (3.3)	484 (3.5)
Solitary pulmonary nodule	1,542 (4.2)	112 (12.1)	101 (8.7)	379 (8.7)	756 (4.9)	667 (3.7)	220 (4.5)	655 (4.7)
Symptoms involving respiratory system and other chest symptoms	873 (2.4)	62 (6.7)	62 (5.3)	216 (5.0)	390 (2.5)	419 (2.3)	108 (2.2)	346 (2.5)
Throat pain	822 (2.2)	13 (1.4)	20 (1.7)	78 (1.8)	347 (2.2)	375 (2.1)	100 (2.0)	347 (2.5)
Tuberous sclerosis complex and others	190 (0.5)	4 (0.4)	3 (0.3)	32 (0.7)	81 (0.5)	99 (0.6)	22 (0.5)	69 (0.5)
Viral infection	2,596 (7.0)	42 (4.6)	62 (5.3)	279 (6.4)	976 (6.3)	1,323 (7.3)	301 (6.1)	972 (7.0)
Viremia, NOS	713 (1.9)	17 (1.8)	29 (2.5)	111 (2.6)	295 (1.9)	321 (1.8)	84 (1.7)	308 (2.2)
Voice disturbance	867 (2.3)	29 (3.1)	24 (2.1)	133 (3.1)	441 (2.9)	370 (2.0)	100 (2.0)	397 (2.9)

**Cade *et al.*: Common pulmonary disease and Covid-19 severity**

Wheezing	1,556 (4.2)	85 (9.2)	90 (7.7)	383 (8.8)	669 (4.3)	726 (4.0)	202 (4.1)	628 (4.5)
----------	----------------	-------------	----------	--------------	--------------	--------------	-----------	--------------

The composite outcome consisted of mechanical ventilation or ICU admission. A breakthrough infection was defined as having occurred >30 days after a second vaccine administration. Values in the three outcome and the breakthrough columns are calculated on the subset of patients who experienced that outcome. Transition dates from the original to the Delta and Omicron variants were set at 7/3/2021 and 12/17/2021 respectively. ICD and PheCode definitions of each disease are provided in Table S1. All values are presented as count (percentage); apart from Age, BMI, and pulmonary and sleep diseases; which are presented as median (interquartile range).

Cade *et al.*: Common pulmonary disease and Covid-19 severity

**Table 2. Associations between preexisting disease and Covid-19 infection severity.**

<b>Existing Disorder</b>	<b>Death Outcome</b>	<b>Mechanical ventilation or ICU admission Outcome</b>	<b>Inpatient admission Outcome</b>
Acute bronchitis and bronchiolitis	1.25 (0.99 – 1.59)	<b>1.43 (1.18 – 1.74)†</b>	<b>1.42 (1.27 – 1.60)†</b>
Acute pharyngitis	0.78 (0.56 – 1.08)	1.05 (0.85 – 1.31)	0.96 (0.85 – 1.08)
Acute sinusitis	0.69 (0.48 – 1.01)	0.94 (0.72 – 1.24)	0.83 (0.72 – 0.97)*
Acute upper respiratory infections of multiple or unspecified sites	0.88 (0.70 – 1.12)	1.12 (0.93 – 1.35)	0.92 (0.83 – 1.02)
Allergy	1.13 (0.95 – 1.34)	1.29 (1.12 – 1.49)*	1.10 (1.01 – 1.19)*
ARDS	<b>2.48 (1.62 – 3.81)†</b>	<b>2.95 (2.03 – 4.29)†</b>	<b>3.90 (3.01 – 5.07)†</b>
Asphyxia and hypoxemia	<b>2.93 (2.21 – 3.89)†</b>	<b>2.36 (1.78 – 3.13)†</b>	<b>5.35 (4.41 – 6.49)†</b>
Asthma	1.18 (0.97 – 1.44)	<b>1.40 (1.20 – 1.64)†</b>	<b>1.28 (1.17 – 1.40)†</b>
Bacterial infection NOS	<b>2.68 (2.06 – 3.48)†</b>	<b>1.96 (1.53 – 2.52)†</b>	<b>2.30 (1.98 – 2.68)†</b>
Bronchitis	1.45 (1.16 – 1.83)*	1.38 (1.12 – 1.70)*	<b>1.40 (1.24 – 1.59)†</b>
Chronic airway obstruction	<b>2.70 (2.22 – 3.28)†</b>	<b>2.42 (1.99 – 2.96)†</b>	<b>3.18 (2.79 – 3.63)†</b>
Chronic bronchitis	<b>2.30 (1.75 – 3.03)†</b>	<b>2.11 (1.59 – 2.78)†</b>	<b>3.53 (2.93 – 4.25)†</b>
Chronic pharyngitis and nasopharyngitis	0.88 (0.64 – 1.21)	0.72 (0.53 – 0.99)*	0.89 (0.76 – 1.04)
Chronic sinusitis	0.84 (0.60 – 1.18)	0.97 (0.73 – 1.28)	0.97 (0.84 – 1.13)
Chronic tonsillitis and adenoiditis	1.06 (0.43 – 2.63)	1.05 (0.57 – 1.94)	1.23 (0.89 – 1.69)
Cough	1.25 (1.07 – 1.46)*	<b>1.31 (1.14 – 1.51)†</b>	<b>1.39 (1.29 – 1.51)†</b>
Emphysema	<b>2.39 (1.87 – 3.05)†</b>	<b>2.90 (2.29 – 3.68)†</b>	<b>3.20 (2.71 – 3.77)†</b>
Empyema and pneumothorax	<b>2.38 (1.76 – 3.21)†</b>	<b>2.04 (1.50 – 2.76)†</b>	<b>2.65 (2.19 – 3.21)†</b>
Epistaxis or throat hemorrhage	<b>1.88 (1.45 – 2.45)†</b>	1.33 (1.01 – 1.74)*	<b>1.35 (1.15 – 1.59)†</b>
Hypersomnia	1.47 (0.88 – 2.46)	1.27 (0.83 – 1.94)	1.27 (1.00 – 1.63)
Influenza	1.47 (1.16 – 1.85)*	<b>1.54 (1.26 – 1.88)†</b>	<b>1.68 (1.49 – 1.89)†</b>
Insomnia	1.09 (0.88 – 1.35)	1.26 (1.04 – 1.52)*	1.09 (0.98 – 1.22)

**Cade et al.: Common pulmonary disease and Covid-19 severity**

<b>Existing Disorder</b>	<b>Death Outcome</b>	<b>Mechanical ventilation or ICU admission Outcome</b>	<b>Inpatient admission Outcome</b>
Lung cancer	<b>3.23 (2.31 – 4.52)<sup>†</sup></b>	1.55 (1.02 – 2.37)*	<b>2.87 (2.25 – 3.66)<sup>†</sup></b>
Lymphangioliomyomatosis	<b>4.57 (2.96 – 7.04)<sup>†</sup></b>	<b>2.54 (1.57 – 4.11)<sup>†</sup></b>	<b>3.82 (2.77 – 5.26)<sup>†</sup></b>
Other diseases of lung	<b>2.13 (1.73 – 2.63)<sup>†</sup></b>	<b>1.66 (1.34 – 2.05)<sup>†</sup></b>	<b>2.33 (2.04 – 2.65)<sup>†</sup></b>
Other dyspnea	<b>2.28 (1.92 – 2.70)<sup>†</sup></b>	<b>1.85 (1.58 – 2.18)<sup>†</sup></b>	<b>2.33 (2.12 – 2.57)<sup>†</sup></b>
Other upper respiratory disease	1.13 (0.89 – 1.42)	1.09 (0.89 – 1.34)	<b>1.23 (1.10 – 1.37)<sup>†</sup></b>
Painful respiration	1.23 (0.96 – 1.60)	1.33 (1.07 – 1.65)*	<b>1.58 (1.40 – 1.79)<sup>†</sup></b>
Parasomnia	1.36 (0.61 – 3.03)	0.85 (0.37 – 1.96)	1.39 (0.93 – 2.09)
Pleurisy; pleural effusion	<b>2.89 (2.33 – 3.58)<sup>†</sup></b>	<b>2.45 (1.97 – 3.04)<sup>†</sup></b>	<b>3.43 (2.97 – 3.96)<sup>†</sup></b>
Pneumonia	<b>2.16 (1.81 – 2.58)<sup>†</sup></b>	<b>2.13 (1.80 – 2.51)<sup>†</sup></b>	<b>2.85 (2.57 – 3.16)<sup>†</sup></b>
Postnasal drip	0.89 (0.64 – 1.24)	1.00 (0.73 – 1.35)	1.02 (0.86 – 1.20)
Pulmonary collapse; interstitial and compensatory emphysema	<b>2.59 (2.10 – 3.18)<sup>†</sup></b>	<b>2.05 (1.66 – 2.54)<sup>†</sup></b>	<b>3.65 (3.19 – 4.17)<sup>†</sup></b>
Pulmonary congestion and hypostasis	<b>3.55 (2.81 – 4.48)<sup>†</sup></b>	<b>3.04 (2.41 – 3.82)<sup>†</sup></b>	<b>5.85 (4.95 – 6.91)<sup>†</sup></b>
Pulmonary embolism and infarction, acute	<b>1.87 (1.36 – 2.56)<sup>†</sup></b>	<b>1.91 (1.42 – 2.56)<sup>†</sup></b>	<b>2.26 (1.87 – 2.72)<sup>†</sup></b>
Pulmonary fibrosis	<b>3.26 (2.22 – 4.78)<sup>†</sup></b>	2.09 (1.39 – 3.16)*	<b>3.03 (2.31 – 3.97)<sup>†</sup></b>
Pulmonary hypertension	<b>3.15 (2.28 – 4.33)<sup>†</sup></b>	<b>2.79 (2.03 – 3.83)<sup>†</sup></b>	<b>3.67 (2.92 – 4.61)<sup>†</sup></b>
Respiratory failure	<b>4.69 (3.54 – 6.21)<sup>†</sup></b>	<b>4.44 (3.41 – 5.78)<sup>†</sup></b>	<b>6.52 (5.31 – 8.01)<sup>†</sup></b>
Restless legs syndrome	1.58 (1.02 – 2.44)*	1.61 (1.08 – 2.41)*	1.38 (1.07 – 1.77)*
Septal deviations / turbinate hypertrophy	0.85 (0.54 – 1.32)	0.63 (0.41 – 0.96)*	<b>0.64 (0.52 – 0.80)<sup>†</sup></b>
Shortness of breath	<b>2.04 (1.74 – 2.40)<sup>†</sup></b>	<b>1.81 (1.56 – 2.10)<sup>†</sup></b>	<b>2.48 (2.27 – 2.71)<sup>†</sup></b>
Sleep apnea	<b>1.68 (1.38 – 2.03)<sup>†</sup></b>	1.32 (1.12 – 1.56)*	<b>1.27 (1.15 – 1.40)<sup>†</sup></b>
Sleep disorders	1.07 (0.76 – 1.50)	0.88 (0.64 – 1.22)	<b>1.35 (1.15 – 1.59)<sup>†</sup></b>
Solitary pulmonary	<b>1.64 (1.31 – 2.04)<sup>†</sup></b>	1.49 (1.20 – 1.86)*	<b>1.56 (1.37 – 1.77)<sup>†</sup></b>

**Cade et al.: Common pulmonary disease and Covid-19 severity**

<b>Existing Disorder</b>	<b>Death Outcome</b>	<b>Mechanical ventilation or ICU admission Outcome</b>	<b>Inpatient admission Outcome</b>
nodule			
Symptoms involving respiratory system and other chest symptoms	<b>2.27 (1.69 – 3.04)<sup>†</sup></b>	<b>1.90 (1.44 – 2.51)<sup>†</sup></b>	<b>1.98 (1.66 – 2.35)<sup>†</sup></b>
Throat pain	0.94 (0.53 – 1.67)	0.92 (0.58 – 1.46)	0.90 (0.70 – 1.16)
Tuberous Sclerosis Complex	1.86 (0.66 – 5.28)	0.71 (0.22 – 2.27)	<b>2.51 (1.66 – 3.80)<sup>†</sup></b>
Viral infection	1.47 (1.05 – 2.05) <sup>*</sup>	1.16 (0.89 – 1.52)	<b>1.51 (1.31 – 1.74)<sup>†</sup></b>
Viremia, NOS	1.30 (0.77 – 2.19)	1.52 (1.03 – 2.25) <sup>*</sup>	<b>1.71 (1.37 – 2.14)<sup>†</sup></b>
Voice disturbance	0.88 (0.59 – 1.31)	0.71 (0.47 – 1.08)	1.03 (0.85 – 1.26)
Wheezing	<b>1.76 (1.37 – 2.26)<sup>†</sup></b>	1.44 (1.14 – 1.81) <sup>*</sup>	<b>2.09 (1.83 – 2.38)<sup>†</sup></b>

Odds ratios with 95% confidence intervals are shown. All association calculations adjusted for age, sex, race/ethnicity, obesity category, and breakthrough infection status. \*:  $p < 0.05$ , †:  $p < 3.3 \times 10^{-4}$  (Bonferroni significance).



*Cade et al.: Common pulmonary disease and Covid-19 severity*

**Table 3. Sex-stratified associations between preexisting disease and death.**

<b>Existing Disorder</b>	<b>Men</b>	<b>Women</b>	<b>P Sex Interaction</b>
Acute bronchitis and bronchiolitis	1.10 (0.77 – 1.59)	1.35 (0.99 – 1.84)	0.366
Acute pharyngitis	0.52 (0.28 – 0.97)*	0.96 (0.65 – 1.42)	0.104
Acute sinusitis	0.33 (0.14 – 0.77)*	0.94 (0.61 – 1.43)	0.035
Acute upper respiratory infections of multiple or unspecified sites	0.67 (0.45 – 1.00)*	1.05 (0.78 – 1.40)	0.063
Allergy	1.01 (0.77 – 1.32)	1.23 (0.98 – 1.54)	0.274
ARDS	2.76 (1.54 – 4.95)*	2.15 (1.14 – 4.07)*	0.621
Asphyxia and hypoxemia	<b>2.68 (1.77 – 4.05)†</b>	<b>3.11 (2.11 – 4.57)†</b>	0.486
Asthma	0.85 (0.61 – 1.19)	1.42 (1.11 – 1.83)*	0.012
Bacterial infection NOS	<b>2.35 (1.57 – 3.53)†</b>	<b>2.93 (2.07 – 4.13)†</b>	0.402
Bronchitis	1.22 (0.86 – 1.74)	1.68 (1.25 – 2.27)*	0.167
Chronic airway obstruction	<b>2.56 (1.93 – 3.40)†</b>	<b>2.84 (2.16 – 3.72)†</b>	0.667
Chronic bronchitis	1.89 (1.23 – 2.89)*	<b>2.64 (1.84 – 3.81)†</b>	0.241
Chronic pharyngitis and nasopharyngitis	0.91 (0.59 – 1.41)	0.86 (0.54 – 1.38)	0.852
Chronic sinusitis	1.14 (0.73 – 1.77)	0.60 (0.35 – 1.02)	0.071
Chronic tonsillitis and adenoiditis	1.35 (0.41 – 4.42)	0.82 (0.20 – 3.41)	0.598
Cough	1.12 (0.89 – 1.40)	1.37 (1.11 – 1.70)*	0.109
Emphysema	<b>2.32 (1.64 – 3.28)†</b>	<b>2.41 (1.70 – 3.42)†</b>	0.976
Empyema and pneumothorax	<b>2.68 (1.85 – 3.88)†</b>	1.87 (1.10 – 3.19)*	0.221
Epistaxis or throat hemorrhage	1.87 (1.30 – 2.69)*	1.89 (1.29 – 2.76)*	0.795
Hypersomnia	1.68 (0.90 – 3.13)	1.21 (0.48 – 3.03)	0.607
Influenza	1.41 (0.99 – 2.00)	1.50 (1.10 – 2.06)*	0.629

**Cade et al.: Common pulmonary disease and Covid-19 severity**

<b>Existing Disorder</b>	<b>Men</b>	<b>Women</b>	<b>P Sex Interaction</b>
Insomnia	1.25 (0.90 – 1.72)	0.99 (0.74 – 1.33)	0.353
Lung cancer	2.39 (1.44 – 3.97)*	<b>4.14 (2.63 – 6.51)†</b>	0.110
Lymphangiomyomas	<b>5.15 (2.93 – 9.04)†</b>	<b>4.07 (2.05 – 8.09)†</b>	0.828
Other diseases of lung	<b>1.86 (1.38 – 2.52)†</b>	<b>2.39 (1.79 – 3.18)†</b>	0.210
Other dyspnea	<b>2.10 (1.65 – 2.67)†</b>	<b>2.44 (1.91 – 3.10)†</b>	0.203
Other upper respiratory disease	1.05 (0.75 – 1.46)	1.22 (0.88 – 1.69)	0.470
Painful respiration	1.37 (0.94 – 1.99)	1.09 (0.76 – 1.55)	0.381
Parasomnia	2.22 (0.88 – 5.58)	0.42 (0.06 – 3.08)	0.143
Pleurisy; pleural effusion	<b>2.60 (1.94 – 3.47)†</b>	<b>3.27 (2.38 – 4.49)†</b>	0.253
Pneumonia	<b>1.98 (1.55 – 2.55)†</b>	<b>2.33 (1.82 – 3.00)†</b>	0.387
Postnasal drip	1.08 (0.67 – 1.72)	0.77 (0.48 – 1.24)	0.399
Pulmonary collapse; interstitial and compensatory emphysema	<b>2.61 (1.99 – 3.42)†</b>	<b>2.51 (1.81 – 3.46)†</b>	0.935
Pulmonary congestion and hypostasis	<b>4.31 (3.11 – 5.96)†</b>	<b>2.87 (2.05 – 4.02)†</b>	0.170
Pulmonary embolism and infarction, acute	1.93 (1.24 – 3.00)*	1.74 (1.11 – 2.73)*	0.899
Pulmonary fibrosis	<b>3.29 (1.90 – 5.71)†</b>	<b>3.35 (1.97 – 5.70)†</b>	0.870
Pulmonary hypertension	<b>3.62 (2.21 – 5.93)†</b>	<b>2.79 (1.84 – 4.25)†</b>	0.570
Respiratory failure	<b>4.12 (2.77 – 6.13)†</b>	<b>5.35 (3.58 – 7.99)†</b>	0.364
Restless legs syndrome	2.08 (1.11 – 3.90)*	1.28 (0.70 – 2.35)	0.377
Septal deviations / turbinate hypertrophy	1.06 (0.63 – 1.79)	0.53 (0.22 – 1.31)	0.191

**Cade et al.: Common pulmonary disease and Covid-19 severity**

<b>Existing Disorder</b>	<b>Men</b>	<b>Women</b>	<b>P Sex Interaction</b>
Shortness of breath	<b>1.84 (1.46 – 2.32)<sup>†</sup></b>	<b>2.22 (1.78 – 2.78)<sup>†</sup></b>	0.123
Sleep apnea	<b>1.68 (1.31 – 2.15)<sup>†</sup></b>	1.79 (1.32 – 2.44)*	0.306
Sleep disorders	1.08 (0.66 – 1.75)	1.07 (0.66 – 1.74)	0.914
Solitary pulmonary nodule	1.56 (1.14 – 2.14)*	1.65 (1.21 – 2.25)*	0.754
Symptoms involving respiratory system and other chest symptoms	2.13 (1.38 – 3.30)*	<b>2.37 (1.58 – 3.53)<sup>†</sup></b>	0.711
Throat pain	0.56 (0.17 – 1.80)	1.20 (0.61 – 2.33)	0.244
Tuberous Sclerosis Complex	0.00 (0.00 – Inf)	3.13 (1.06 – 9.28)*	0.945
Viral infection	1.36 (0.82 – 2.25)	1.54 (0.99 – 2.42)	0.746
Viremia, NOS	0.71 (0.28 – 1.84)	1.85 (0.99 – 3.46)	0.093
Voice disturbance	0.96 (0.54 – 1.70)	0.82 (0.48 – 1.43)	0.747
Wheezing	<b>2.03 (1.41 – 2.93)<sup>†</sup></b>	1.53 (1.08 – 2.17)*	0.441

Associations with a death outcome are shown using odds ratios with 95% confidence intervals. Results from all three outcomes can be found in Table S2. All association calculations adjusted for age, sex, race/ethnicity, obesity category, and breakthrough infection status. \*:  $p < 0.05$ , †:  $p < 1.6 \times 10^{-4}$  (Bonferroni significance).

Cade *et al.*: Common pulmonary disease and Covid-19 severity

**Table 4. Date-specific associations between preexisting disease and death.**

Existing disease	Pre-Delta variant majority dates	Delta variant majority dates	Omicron variant majority dates
Acute bronchitis and bronchiolitis	1.25 (0.94 – 1.67)	1.08 (0.52 – 2.25)	1.25 (0.75 – 2.08)
Acute pharyngitis	0.79 (0.52 – 1.19)	0.53 (0.16 – 1.73)	0.91 (0.50 – 1.67)
Acute sinusitis	0.65 (0.40 – 1.06)	0.65 (0.23 – 1.82)	0.81 (0.39 – 1.68)
Acute upper respiratory infections of multiple or unspecified sites	0.89 (0.66 – 1.20)	1.31 (0.73 – 2.35)	0.71 (0.43 – 1.16)
Allergy	1.12 (0.90 – 1.40)	1.02 (0.60 – 1.71)	1.20 (0.85 – 1.70)
ARDS	2.55 (1.47 – 4.40)*	2.77 (0.88 – 8.71)	2.33 (0.96 – 5.63)
Asphyxia and hypoxemia	<b>3.39 (2.40 – 4.80)<sup>†</sup></b>	1.53 (0.50 – 4.65)	2.52 (1.40 – 4.53)*
Asthma	1.13 (0.88 – 1.46)	1.24 (0.69 – 2.22)	1.34 (0.91 – 1.97)
Bacterial infection NOS	<b>3.00 (2.16 – 4.16)<sup>†</sup></b>	3.91 (1.89 – 8.05)*	1.63 (0.90 – 2.95)
Bronchitis	1.45 (1.09 – 1.94)*	1.43 (0.73 – 2.80)	1.43 (0.90 – 2.26)
Chronic airway obstruction	<b>2.59 (2.02 – 3.33)<sup>†</sup></b>	2.19 (1.15 – 4.18)*	<b>3.47 (2.39 – 5.04)<sup>†</sup></b>
Chronic bronchitis	<b>2.26 (1.58 – 3.23)<sup>†</sup></b>	1.84 (0.69 – 4.91)	<b>3.07 (1.87 – 5.03)<sup>†</sup></b>
Chronic pharyngitis and nasopharyngitis	0.86 (0.57 – 1.30)	1.25 (0.58 – 2.71)	0.79 (0.40 – 1.56)
Chronic sinusitis	0.90 (0.59 – 1.39)	0.99 (0.42 – 2.35)	0.64 (0.30 – 1.35)
Chronic tonsillitis and adenoiditis	1.90 (0.74 – 4.84)	N/A	N/A
Cough	1.15 (0.94 – 1.40)	1.71 (1.09 – 2.69)*	1.30 (0.95 – 1.78)
Emphysema	<b>2.35 (1.71 – 3.24)<sup>†</sup></b>	1.91 (0.87 – 4.22)	<b>2.86 (1.83 – 4.48)<sup>†</sup></b>
Empyema and pneumothorax	<b>2.83 (1.95 – 4.12)<sup>†</sup></b>	1.24 (0.45 – 3.42)	1.94 (1.03 – 3.65)*
Epistaxis or throat hemorrhage	<b>1.97 (1.42 – 2.74)<sup>†</sup></b>	1.63 (0.71 – 3.72)	1.69 (0.99 – 2.87)

**Cade et al.: Common pulmonary disease and Covid-19 severity**

<b>Existing disease</b>	<b>Pre-Delta variant majority dates</b>	<b>Delta variant majority dates</b>	<b>Omicron variant majority dates</b>
Hypersomnia	1.23 (0.61 – 2.50)	1.23 (0.25 – 6.10)	2.30 (0.98 – 5.40)
Influenza	1.72 (1.29 – 2.30)*	1.57 (0.79 – 3.13)	0.90 (0.53 – 1.55)
Insomnia	1.17 (0.89 – 1.54)	1.61 (0.89 – 2.92)	0.78 (0.49 – 1.22)
Lung cancer	<b>3.44 (2.20 – 5.38)<sup>†</sup></b>	1.52 (0.43 – 5.45)	<b>3.75 (2.11 – 6.65)<sup>†</sup></b>
Lymphangioliomyomatosis	<b>4.76 (2.59 – 8.72)<sup>†</sup></b>	2.08 (0.45 – 9.72)	<b>5.42 (2.69 – 10.93)<sup>†</sup></b>
Other diseases of lung	<b>2.12 (1.63 – 2.75)<sup>†</sup></b>	1.27 (0.61 – 2.65)	<b>2.69 (1.81 – 3.98)<sup>†</sup></b>
Other dyspnea	<b>2.20 (1.76 – 2.74)<sup>†</sup></b>	<b>2.79 (1.71 – 4.54)<sup>†</sup></b>	<b>2.26 (1.61 – 3.17)<sup>†</sup></b>
Other upper respiratory disease	1.23 (0.92 – 1.66)	1.15 (0.59 – 2.24)	0.98 (0.62 – 1.56)
Painful respiration	1.19 (0.86 – 1.65)	0.69 (0.27 – 1.77)	1.64 (1.02 – 2.66)*
Parasomnia	1.90 (0.77 – 4.71)	N/A	0.81 (0.11 – 6.14)
Pleurisy; pleural effusion	<b>2.89 (2.18 – 3.81)<sup>†</sup></b>	<b>4.44 (2.37 – 8.31)<sup>†</sup></b>	<b>2.61 (1.73 – 3.96)<sup>†</sup></b>
Pneumonia	<b>2.38 (1.91 – 2.97)<sup>†</sup></b>	2.50 (1.47 – 4.26)*	1.59 (1.10 – 2.30)*
Postnasal drip	0.85 (0.54 – 1.32)	1.45 (0.64 – 3.30)	0.81 (0.42 – 1.54)
Pulmonary collapse; interstitial and compensatory emphysema	<b>2.33 (1.78 – 3.05)<sup>†</sup></b>	3.13 (1.70 – 5.78)*	<b>3.00 (2.03 – 4.42)<sup>†</sup></b>
Pulmonary congestion and hypostasis	<b>3.43 (2.54 – 4.63)<sup>†</sup></b>	<b>5.37 (2.80 – 10.29)<sup>†</sup></b>	<b>3.06 (1.90 – 4.94)<sup>†</sup></b>
Pulmonary embolism and infarction, acute	1.68 (1.12 – 2.53)*	1.17 (0.44 – 3.12)	2.92 (1.66 – 5.16)*
Pulmonary fibrosis	<b>3.63 (2.25 – 5.86)<sup>†</sup></b>	1.33 (0.16 – 10.78)	2.96 (1.41 – 6.20)*
Pulmonary hypertension	<b>3.25 (2.17 – 4.88)<sup>†</sup></b>	3.82 (1.63 – 8.98)*	2.33 (1.16 – 4.69)*
Respiratory failure	<b>5.62 (3.92 – 8.07)<sup>†</sup></b>	<b>5.36 (2.34 – 12.27)<sup>†</sup></b>	<b>3.51 (1.99 – 6.17)<sup>†</sup></b>

**Cade et al.: Common pulmonary disease and Covid-19 severity**

<b>Existing disease</b>	<b>Pre-Delta variant majority dates</b>	<b>Delta variant majority dates</b>	<b>Omicron variant majority dates</b>
Restless legs syndrome	1.65 (0.96 – 2.84)	0.71 (0.09 – 5.41)	1.83 (0.83 – 4.07)
Septal deviations / turbinate hypertrophy	1.22 (0.72 – 2.05)	0.57 (0.14 – 2.40)	0.42 (0.13 – 1.33)
Shortness of breath	<b>2.09 (1.71 – 2.57)<sup>†</sup></b>	1.75 (1.06 – 2.87)*	<b>2.16 (1.58 – 2.96)<sup>†</sup></b>
Sleep apnea	<b>1.83 (1.44 – 2.33)<sup>†</sup></b>	1.64 (0.94 – 2.88)	1.35 (0.89 – 2.04)
Sleep disorders	1.39 (0.94 – 2.06)	0.48 (0.11 – 2.03)	0.57 (0.23 – 1.41)
Solitary pulmonary nodule	1.47 (1.09 – 1.97)*	1.37 (0.71 – 2.63)	<b>2.24 (1.52 – 3.29)<sup>†</sup></b>
Symptoms involving respiratory system and other chest symptoms	<b>2.31 (1.57 – 3.39)<sup>†</sup></b>	2.54 (1.16 – 5.57)*	2.07 (1.14 – 3.76)*
Throat pain	0.78 (0.33 – 1.82)	1.44 (0.33 – 6.31)	1.19 (0.47 – 3.03)
Tuberous Sclerosis Complex	1.85 (0.55 – 6.25)	N/A	1.92 (0.23 – 15.79)
Viral infection	1.44 (0.94 – 2.20)	1.24 (0.38 – 4.12)	1.83 (0.99 – 3.39)
Viremia, NOS	1.77 (0.97 – 3.23)	N/A	0.91 (0.28 – 2.96)
Voice disturbance	0.98 (0.59 – 1.61)	0.24 (0.03 – 1.81)	0.98 (0.48 – 1.99)
Wheezing	1.83 (1.33 – 2.51)*	2.19 (1.08 – 4.46)*	1.60 (0.95 – 2.70)

Associations with a death outcome are shown using odds ratios with 95% confidence intervals. Results from all three outcomes and sex-stratified associations can be found in Table S4. Transition dates from the pre-Delta to the Delta and Omicron variants were set at 7/3/2021 and 12/17/2021 respectively. All association calculations adjusted for age, sex, race/ethnicity, obesity category, and breakthrough infection status. N/A: no observed outcomes. \*:  $p < 0.05$  †:  $p < 1.1 \times 10^{-4}$  (Bonferroni significance).

*Cade et al.: Common pulmonary disease and Covid-19 severity*

**Table 5. Joint pulmonary and sleep disorders LASSO regression nonzero coefficients.**

<b>Disease or covariate</b>	<b>Death Outcome</b>	<b>Mechanical ventilation or ICU admission Outcome</b>	<b>Inpatient admission Outcome</b>
Age	1.610	0.780	0.826
BMI	0	0.076	0
Sex (1M, 2F)	-0.089	-0.149	-0.042
Breakthrough Infection	0	-0.074	-0.250
Encounters	0.071	0.116	0.296
Days into pandemic (1/1/2020)	-0.442	-0.734	-0.222
Emphysema	N/A	0.071	N/A
Pneumonia	0.039	N/A	0.105
Chronic airway obstruction	0.093	N/A	N/A
Pulmonary congestion and hypostasis	N/A	0.059	0.097
Respiratory failure	0.091	N/A	0.075
Shortness of breath	N/A	N/A	0.141

Nonzero coefficients from adaptive LASSO regressions predicting each outcome using all pulmonary and sleep diseases and covariates are shown. Greater absolute values indicate greater relative importance. The covariates age, sex, BMI, race/ethnicity, breakthrough infection status, total healthcare encounters, and days into the pandemic were forced into all training, testing and combined sample runs. Sex-stratified results are listed in Table S5. N/A: not included in final combined sample run. Association odds ratios for individual diseases are presented in Tables 2 and S2.


**Cade *et al.*: Common pulmonary disease and Covid-19 severity**

391 **Acknowledgments**

392 The authors wish to thank the MGB Research Patient Data Registry (RPDR) and  
393 patients for providing health information data.



Combined Sex Death Outcome Disease



Adjusted covariate